Financial Data and Key Metrics Changes - Q3 revenue exceeded $1 billion, marking a 10.7% increase compared to 2024 [9] - Organic revenue grew by 5.9%, driven by favorable pricing and volume, particularly in the Americas nonresidential business [10] - Adjusted earnings per share (EPS) for Q3 was $2.3, an increase of $0.14 or 6.5% year-over-year [10] - Year-to-date available cash flow reached $485.2 million, up 25.1% compared to the previous year [11] Business Line Data and Key Metrics Changes - Americas segment revenue was $844 million, up 7.9% reported and 6.4% organically, with strong performance in nonresidential business [12] - International segment revenue was $226 million, up 22.5% reported and 3.6% organically, led by electronics businesses [15] - Adjusted operating margin for the Americas increased by 40 basis points, while the international segment's adjusted operating margin rose by 70 basis points [14][15] Market Data and Key Metrics Changes - Nonresidential markets in the Americas remain resilient, with solid demand and spec activity growth [19] - Residential markets are considered soft, with growth primarily driven by new electronic product launches [13][19] - International markets are expected to show roughly flat organic performance, with some segments at historical troughs [21] Company Strategy and Development Direction - The company is focused on capital allocation for long-term shareholder benefits, raising the 2025 adjusted EPS outlook to $8.1 to $8.2 [6][20] - Recent acquisitions, including UAP and Bressant, are aimed at strengthening the product portfolio and enhancing cost position [7][20] - The company emphasizes disciplined capital deployment and continues to seek accretive acquisitions in high-performing markets [32][58] Management's Comments on Operating Environment and Future Outlook - Management noted a positive environment for nonresidential project activity, with healthy customer backlogs supporting organic growth [38] - The input cost environment remains dynamic, with expectations to drive pricing to offset inflation [21][76] - Overall, the company remains confident in its ability to navigate the current economic landscape and achieve growth [22] Other Important Information - The company has allocated approximately $600 million to acquisitions year-to-date, consistent with priorities outlined at the Investor Day [5] - The balance sheet remains strong, with a net debt to adjusted EBITDA ratio of 1.8 times [17] Q&A Session Summary Question: Update on spec writing and key verticals - Spec activity has continued to grow in 2025, supporting organic growth in nonresidential markets [28][30] Question: M&A pipeline and potential earnings accretion - The M&A pipeline remains strong across both reporting segments, with ongoing activity in various product categories [32] Question: Conversations with building owners and architects regarding macro uncertainty - Nonresidential project activity is performing well, with private finance returning to the market [38] Question: International volume growth and momentum - International segment showed positive volume growth, with expectations for continued performance despite a largely unchanged market outlook [40] Question: Adjusted operating margins and corporate costs - Expectation of margin expansion in Q4, with corporate costs remaining consistent with previous quarters [46] Question: Residential outlook for Q4 - Residential market demand is expected to remain soft, aligning with year-to-date growth rates [74] Question: Pricing power and customer reactions to tariffs - The company has not observed pricing fatigue, with strong pricing power maintained in the current environment [76]

Financial Data and Key Metrics Changes - Year-over-year revenue increased by 14.7%, driven entirely by organic growth, keeping within the anticipated range for organic growth during the year [23] - Gross margin for the quarter was 58.3%, down from 59.8% in 2024 and 56.3% in 2025, reflecting a decline consistent with previous quarters [23][24] - Adjusted EBITDA grew 12% year-over-year to $14.3 million, with an adjusted EBITDA margin of 22.7% [24][30] Business Line Data and Key Metrics Changes - Ventilation business accounted for 54% of revenues, with vent revenue up 5% sequentially and 11% year-over-year [11][23] - Sleep therapy patients increased by 15% sequentially and 51% year-over-year, with new patient sales up 72% year-over-year [12][23] - Resupply program patients were up 10% sequentially and 25% year-over-year, indicating strong growth in this segment [13] - Staffing business experienced a sequential slowdown due to softened labor demand, although it was up year-over-year [14][20] Market Data and Key Metrics Changes - The sleep business now represents 19% of total revenues, reflecting its rapid growth and importance to the overall revenue mix [23][45] - The staffing business, which accounts for approximately 10% of total revenue, is primarily driven by behavioral and social service needs [20] Company Strategy and Development Direction - The company is focused on expanding its addressable at-home market, with the acquisition of Lehan Medical Equipment marking a strategic step into maternal health [8][10] - The company aims to diversify its patient base and leverage existing infrastructure to reach new patient populations [8][10] - The management emphasizes disciplined execution of long-term strategies, resulting in tangible growth across core and complementary services [6][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the evolving regulatory landscape, particularly with the new NCD final rule, which is expected to reduce operational burdens [15][18] - The company anticipates continued organic growth and has raised its full-year guidance for net revenue and adjusted EBITDA, reflecting optimism for the second half of the year [30][32] - Management noted that the industry is well-positioned to educate regulators and present solutions, enhancing the company's competitive stance [18][19] Other Important Information - The company has a strong balance sheet with $55 million available on credit facilities and $20 million in cash, enabling share repurchase programs and acquisitions [28][29] - The company completed a ventilator exchange program, which is expected to normalize CapEx going forward and improve adjusted free cash flow [26][30] Q&A Session Summary Question: Can you elaborate on the benefits of the BENT program upgrade and exchanges? - The financial benefits include cash back for the vents, generally higher than net book value, and the clinical value lies in acquiring newer, technologically advanced assets [35][36] Question: What is the administration's view on DME in general? - The administration is looking to cut costs across government sectors, and competitive bidding pressure is anticipated [39][40] Question: Were there any unusual factors contributing to the growth in sleep therapy patient count? - Growth is attributed to an expanded sales force and increased operational efficiency, with no significant negative impact from GLP-1s [44][45] Question: What drove the decline in service revenue in the staffing business in Q2? - The decline is linked to behavioral health and social service needs, with expectations for appropriations to improve in the back half of the year [48][49]